Kavita Ahuja, DO
Nephrology · Monroe, NJNPI 1255592515
Payments from drug & device makers
Across 21 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aesculap Biologics, LLC$149
- Vifor Pharma, Inc.$69
- Amgen$63
- AstraZeneca$27
- Daiichi Sankyo Inc.$27
- Bayer$20
- plus $69 from 5 others
What the payments were for
- Food & beverage$41999%
- Education$51%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aesculap Biologics, LLC | 1 | $149 |
| Vifor Pharma, Inc. | 5 | $69 |
| Amgen(2 entities) | 4 | $63 |
| AstraZeneca | 2 | $27 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Bayer | 1 | $20 |
| GSK | 1 | $18 |
| Calliditas Therapeutics US Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $14 |
| OPKO Pharmaceuticals, LLC | 1 | $12 |
| Travere Therapeutics, Inc. | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NOVOCART 3D$149
How this compares
$424 in reported general payments places this provider in the 30th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 13 | $7,334 |
| ClinisolParenteral Amino Acid 15% No.5 | 52 | $4,769 |
| Sevelamer Carbonate | 11 | $4,289 |
| ProsolParenteral Amino Acid 20% No.1 | 35 | $3,671 |
| Valsartan | 55 | $1,351 |
| Amlodipine Besylate | 120 | $1,168 |
| Calcium Acetate | 11 | $894 |
| Torsemide | 35 | $646 |
| Potassium Chloride | 27 | $608 |
| Midodrine Hcl | 11 | $438 |
| Enalapril Maleate | 21 | $376 |
| Hydralazine Hcl | 13 | $361 |
| Allopurinol | 25 | $286 |
| Losartan Potassium | 32 | $275 |
| Clonidine Hcl | 22 | $268 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Monroe
- Ojas MehtaMonroe$28K
- Danny HaddadJersey City$1.7M
- Anup PatelWest Orange$1M
- Joshua KaplanNewark$509K
- Lawrence ByrdLivingston$338K
- Devang LodhaviaVoorhees$321K
- Jeffrey FeldmanUnion$315K
- Kenneth LissEatontown$271K
- Narender GoelJersey City$181K
- Vadim FinkielsteinPrinceton Junction$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.